Physician profile
Sam Joseph
NPI 1659833424
$2,792.67
in general payments reported to CMS, 2019-2025
22 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $217 · 2023: $1,200 · 2024: $1,015 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.37 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $570.90 | 2022-2025 | Minimed 780g, Minimed 770g |
| Novo Nordisk INC | $477.94 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $281.46 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $246.22 | 2021-2024 | Farxiga |
| Alexion Pharmaceuticals, INC. | $190.77 | 2023-2024 | Strensiq |
| Lilly USA, LLC | $165.09 | 2024 | Mounjaro, Jardiance, Zepbound |
| Radius Health, INC. | $126.54 | 2023-2024 | Tymlos |
| Amgen INC. | $121.77 | 2022-2024 | Krystexxa, Tepezza |
| Abbvie INC. | $98.51 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $92.14 | 2023-2024 | Lupkynis |
| Averitas Pharma INC. | $76.47 | 2023-2024 | Qutenza |
| Ucb, INC. | $56.17 | 2024 | Cimzia |
| Ascensia Diabetes Care US INC. | $55.71 | 2023-2024 | |
| Daiichi Sankyo INC. | $44.07 | 2023-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.04 | 2023 | Jardiance, Ofev |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $38.12 | 2022 | |
| Kyowa Kirin, INC. | $26.58 | 2024 | Crysvita |
| Otsuka America Pharmaceutical, INC. | $22.39 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $14.70 | 2023 | Trintellix |
| Halozyme INC | $14.67 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.33 | 2024 | |
| Boston Scientific Corporation | $14.08 | 2023 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.